Patents by Inventor Lourdes Tatiana Roque Navarro
Lourdes Tatiana Roque Navarro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210230624Abstract: An expression vector for the co-expression of different polynucleotides in microalgal cells and to the expression cassettes having both polynucleotides is provided. Also provided are a host cell, a method for expressing the proteins of interest and a method for selecting a cell co-expressing two proteins of interest in a stoichiometric manner.Type: ApplicationFiled: May 9, 2019Publication date: July 29, 2021Inventors: Olga DURANY TURK, Jordi SEGURA DE YEBRA, Jaume MERCADE ROCA, Maria Teresa LOPEZ CERRO, Cristina LOPEZPAZ, Lourdes Tatiana ROQUE NAVARRO
-
Patent number: 9914768Abstract: The present invention relates to the use of antibodies against S100A7 protein for the prevention and/or treatment of cancer or a disease associated to an undesired angiogenesis or a disease associated with inflammation; and to methods and kits for diagnosing and determining the prognostic of said diseases in vitro and in vivo by means of detecting levels of S100A7 in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100A7 monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as pharmaceutical compositions and conjugates containing them.Type: GrantFiled: April 9, 2014Date of Patent: March 13, 2018Assignee: Lykera Biomed, S.A.Inventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
-
Patent number: 9868784Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.Type: GrantFiled: December 7, 2015Date of Patent: January 16, 2018Assignee: LYKERA BIOMED SAInventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
-
Patent number: 9657092Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.Type: GrantFiled: November 25, 2014Date of Patent: May 23, 2017Inventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
-
Publication number: 20160289307Abstract: The present invention relates to the use of antibodies against S100A7 protein for the prevention and/or treatment of cancer or a disease associated to an undesired angiogenesis or a disease associated with inflammation; and to methods and kits for diagnosing and determining the prognostic of said diseases in vitro and in vivo by means of detecting levels of S100A7 in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100A7 monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as pharmaceutical compositions and conjugates containing them.Type: ApplicationFiled: April 9, 2014Publication date: October 6, 2016Applicant: LYKERA BIOMED SAInventors: José Luis HERNÁNDEZ MÍGUEZ, Jaume ADAN PLANA, Josep Maria MARTÍNEZ ESCOLÀ, Marc MASA ÁL VAREZ, Ramon MESSEGUER PEYPOCH, Francesc MITJANS PRAT, Sheila DAKHEL PLAZA, Antonio COLL MANZANO, Rosa Mª HERVAS VILLEGAS, Carme CALVIS CALPE, Laura PADILLA GARCÍA, Lourdes Tatiana ROQUE NAVARRO, Laura BARBERÀ FERRANDO, Manuel RIVAS CANAS
-
Publication number: 20160090412Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.Type: ApplicationFiled: December 7, 2015Publication date: March 31, 2016Inventors: José Luis HERNÁNDEZ MÍGUEZ, Jaume ADAN PLANA, Josep Maria MARTÍNEZ ESCOLÀ, Marc MASA ÁLVAREZ, Ramon MESSEGUER PEYPOCH, Francesc MITJANS PRAT, Sheila DAKHEL PLAZA, Antonio COLL MANZANO, Rosa Mª HERVAS VILLEGAS, Carme CALVIS CALPE, Laura PADILLA GARCÍA, Lourdes Tatiana ROQUE NAVARRO, Laura BARBERÀ FERRANDO, Manuel RIVAS CAÑAS
-
Patent number: 9228011Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.Type: GrantFiled: January 17, 2012Date of Patent: January 5, 2016Assignee: Lykera Biomed SAInventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
-
Publication number: 20150079097Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Inventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
-
Patent number: 8916152Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.Type: GrantFiled: June 14, 2011Date of Patent: December 23, 2014Assignee: Lykera Biomed SAInventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
-
Patent number: 8758753Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.Type: GrantFiled: March 19, 2009Date of Patent: June 24, 2014Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
-
Publication number: 20130101592Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.Type: ApplicationFiled: June 14, 2011Publication date: April 25, 2013Applicant: LYKERA BIOMED SAInventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
-
Publication number: 20100297008Abstract: The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10 (MAbai 1E10) produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specific binding to the antigen of the original antibodies, but being at the same time less immunogenic.Type: ApplicationFiled: March 19, 2009Publication date: November 25, 2010Inventors: Cristina Maria Mateo de Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
-
Patent number: 6891023Abstract: Novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101. The recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.Type: GrantFiled: November 16, 2000Date of Patent: May 10, 2005Assignee: Centro Inmunologia MolecularInventors: Cristina Maria Mateo de Acosta Del Rio, Lourdes Tatiana Roque Navarro, Alejo Morales Morales, Rolando Pérez Rodríguez, Marta Ayala Ávila, Jorge Victor Gavilondo Cowley, Marta Dueñas Porto, Hanssel Bell García, Enrique Rengifo Calzado, Normando Iznaga Escobar, Mayra Ramos Zuzarte
-
Publication number: 20040253233Abstract: The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10) produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specific binding to the antigen of the original antibodies, but being at the same time less immunogenic.Type: ApplicationFiled: November 17, 2003Publication date: December 16, 2004Inventors: Cristina Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena